<DOC>
	<DOCNO>NCT00381342</DOCNO>
	<brief_summary>This Phase 3 trial design compare effect twice-daily exenatide twice-daily placebo respect glycemic control drug-naive patient type 2 diabetes treat diet exercise .</brief_summary>
	<brief_title>Safety Efficacy Exenatide Monotherapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Diagnosed type 2 diabetes Treating diabetes diet exercise HbA1c 6.5 % 10.0 % , inclusive Body Mass Index ( BMI ) 25 kg/m^2 45 kg/m^2 , inclusive Have previously complete withdrawn study Have receive treatment within last 30 day drug receive regulatory approval indication time study entry Have treat antidiabetic agent Have use drug weight loss ( example , Xenical , Meridia , Acutrim , similar overthe counter medication ) within 3 month screen Are currently treat follow excluded medication : * drug directly affect gastrointestinal motility ; * systemic corticosteroid ( exclude topical inhale preparation ) oral , intravenous , intramuscular route use regularly ( longer 2 week ) use within 2 week immediately prior screen study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>exenatide</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
	<keyword>monotherapy</keyword>
</DOC>